FDA approved the drug Victoza for the treatment of diabetes type

US Food and Drug Administration USA (FDA) approved the drug Victoza (liraglutide) for the treatment of diabetes type 2. Victoza is made by one of the largest pharmaceutical companies in Denmark, Novo Nordisk. Victoza is available in the form of injection and used once a day for the treatment of type 2 diabetes.

However, it still requires further studies and research in order to approve this medicine as a first-line therapy. Currently FDA approved liraglutide for lowering blood sugar levels in combination with diet, exercise and other drugs.

In April 2009, 6 of the 13-member expert committee of FDA voted against approval of the drug, and one abstained. The reason of that were the doubts that emerged in expert committee, after some clinical tests pointed to the possibility of thyroid cancer associated with the application of Victoza (liraglutide).
Currently there is no exact answer whether the drug can cause thyroid cancer in humans. It requires additional long-term studies of application. The medication will be available on the pharmaceutical market in 2 weeks.